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Background: Mammary tumours are the most common malignancy diagnosed in female dogs and a significant
cause of mortality and morbidity in this species. Carbohydrate antigen (CA) 15–3 is a mucinous glycoprotein
aberrantly over-expressed in human mammary neoplasms and one of the most widely used serum tumour markers
in women with breast cancer. The aim of this study was to investigate the antigenic analogies of human and
canine CA 15–3 and to assess its expression in canine mammary cancer tissues and cell lines. Immunohistochemical
expression of CA 15–3 was evaluated in 7 canine mammary cancer cell lines and 50 malignant mammary tumours.
As a positive control, the human breast carcinoma cell line MCF7 and tissue were used. To assess CA 15–3 staining,
a semi-quantitative method was applied. To confirm the specificity and cross-reactivity of an anti-human CA 15–3
antibody to canine tissues, an immunoblot analysis was performed. We also investigated serum CA 15–3 activity to
establish whether its expression could be assigned to several tumour characteristics to evaluate its potential use as
a serum tumour marker in the canine mammary oncology field.
Results: Immunocytochemical analysis revealed CA 15–3 expression in all examined canine mammary cancer cell
lines, whereas its expression was confirmed by immunoblot only in the most invasive cells (CMT-W1, CMT-W1M,
CMT-W2 and CMT-W2M). In the tissue, an immunohistochemical staining pattern was observed in 34 (68%) of the
malignant tumours. A high statistical correlation (p = 0.0019) between serum CA 15–3 levels and the degree of
tumour proliferation and differentiation was shown, which indicates that the values of this serum marker increase
as the tumour stage progresses.
Conclusions: The results of this study reveal that CA 15–3 is expressed in both canine mammary tumour cell lines
and tissues and that serum levels significantly correlate with the histological grade of the malignancy.Background
Spontaneous mammary tumours are commonly observed
in female dogs, particularly in many European countries
where animals are not routinely spayed at a young age.
The majority of malignant tumours arise from epithelial
tissue and metastasise to the lungs or other organs [1].
Several histopathological variables, such as tumour
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reproduction in any medium, provided the orand the tumour grade of differentiation form, have been
widely used parameters in prognostic evaluations [2,3].
In human breast cancer and other malignancies, serum
tumour markers play an important role in patient man-
agement [4,5]. Tumour cells display protein molecules on
their surfaces. These proteins, called tumour-associated
antigens, may be present in higher than usual concentra-
tions in other tissues, serum, urine or body fluids of
patients with cancer. Thus, the elevation of these markers
may be helpful in early diagnosis, determining prognosis,
following a course of treatment, predicting the response
or resistance to specific therapies and surveillance after
primary surgery [6,7].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the product of the mucin 1 gene, is a large transmem-
brane glycosylated molecule aberrantly overexpressed in
many adenocarcinomas in an underglycosylated form
and then shed into the circulation [8,9]. The antigen
bears epitopes that are recognised by two murine mono-
clonal antibodies: the high molecular weight mucin-like
glycoprotein DF3 (mucin 1 gene-derived), raised against
a membrane fraction of liver metastasis from breast can-
cer, and 115d8, raised against a milk fat globule mem-
brane [10,11]. During a malignant transformation, the
membrane expression of the MUC1 cell surface-
associated oncoprotein often changes from apical to cir-
cumferential simultaneously with a loss of polarity of the
epithelial cells, acting as anti-adhesive molecules and fa-
cilitating the detachment of malignant cells, and increas-
ing the metastatic and invasive potential of tumour cells
[12]. Currently, CA 15–3, the circulating form of DF3
antigen, is one of the most widely used serum biochem-
ical markers in breast cancer. High serum levels in pre-
operative patients correlate with large-size tumours, the
stage of the disease and the presence of lymph node me-
tastases and are associated with an adverse patient out-
come [13,14].
In spite of the advanced diagnostic tools available in
human oncology, the methodologies available in veterin-
ary medicine may still be considered to be in progress,
and there is a need to develop reliable and easily per-
formed diagnostic tests that may predict an increasing
tumour burden or recurrence after a mastectomy in the
individual patient and prove more useful in terms of
classification and prognosis.
Currently, there is a lack of scientific documentation
regarding the application of serum tumour markers in
the canine mammary oncology field, and only one pre-
liminary report describing the possible use of serum CA
15–3 in dogs has been published [15]. The Authors
showed that the application of direct chemiluminescence
using a human commercial kit appears to be a promising
method for the determination of CA 15–3 levels in ca-
nine mammary oncology.
The present study was therefore designed to verify the
antigenic correlation of human and canine CA 15–3, to
assess the expression profile of this tumour-associated
antigen and to establish whether its expression could be
associated with several tumour characteristics to evalu-
ate its potential use as a serum tumour marker in the ca-




The seven canine cell lines used for this study have pre-
viously been recounted [16-19]. Two of the cell linesused in this study originated from mammary adenocar-
cinomas (CMT-W1 and CMT-W2), and two of the cell
lines originated from their metastases to the lungs
(CMT-W1M and CMT-W2M, respectively); these cell
lines were kindly donated by Prof. Dr. Maciej Ugorski
and Dr. Joanna Polańska of the Wrocław University of
Environmental and Life Sciences in Poland. One cell line
originated from canine mammary anaplastic cancer
(P114) and was kindly provided by Dr. Gerard Rutteman
of Utrecht University in the Netherlands. Two canine can-
cer cell lines were kindly provided by Dr. Eva Hellmen of
the Swedish University of Agricultural Sciences (Sweden):
mammary carcinoma (CMT-U27) and spindle-cell mam-
mary tumour (CMT-U309). The cell lines were routinely
cultured in RPMI-1640 medium (Sigma Aldrich, USA)
enriched with 10% foetal bovine serum (FBS) (Gibco,
USA), penicillin-streptomycin (50 IU/ml) and fungizone
(2.5 mg/ml) (Sigma Aldrich, USA) under conditions of 5%
CO2/95% humidified air at 37 °C.
Human breast adenocarcinoma cell line (MCF7) was
kindly provided by Dr. Luisa Lanfrancone of Campus
IFOM-IEO Milano (Italy). This cell line was grown in Dul-
becco’s modified Eagle’s medium (DMEM) (Gibco, USA)
supplemented with 10% FBS (Gibco, USA), 100 IU/ml
penicillin and 100 μg/ml streptomycin (Sigma Aldrich,
USA) at 37 °C in a humidified atmosphere with 5% CO2.
Immunocytochemistry (ICC)
Cells were cultured on Lab Tek (Nunc Inc., DK) 4-
chamber culture slides and were fixed with 70% ethanol
after 24 hours. After washing with Tris buffered saline
(TBS) (Dako, DK), the samples were incubated in Perox-
idase Blocking Reagent (Dako, DK) for 10 min at room
temperature. After a 30 min incubation in TBS with 5%
bovine serum albumin (BSA) (Sigma Aldrich, USA), the
anti DF3 (Imgenex, USA) and anti 115d8 (Abcam, UK)
monoclonal antibodies, diluted 1:100 in 1% BSA, were
used, and then the slides were incubated at +4 °C over-
night. For staining, the EnVision kit (Dako, DK) was
used. To develop the coloured product, the 3,3`-
Diaminobenzidine (DAB) substrate (Dako, DK) was used.
Finally, haematoxylin was used for nuclei counterstaining.
For immunocytochemical experiments, the negative
control samples stained without the use of primary anti-
bodies were set aside. Four independent experiments
were conducted.
Ten pictures of each slide were taken using Olympus
microscopy BX60 (Olympus, DE). The colorimetric in-
tensity of the ICC-stained antigen spots (brown colour)
was measured by a computer-assisted image analyser
(Olympus Microimage™ Image Analysis, software version
4.0 for Windows, USA). The antigen spot colour inten-
sity is expressed as the mean pixel optical density on a
1–256 scale.
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The invasion assay and 3D culture of the canine mam-
mary cancer cell lines CMT-U27, CMT-U309, P114,
CMT-W1 and CMT-W2 has been previously reported
[20]. BD BioCoat Matrigel™ invasion chambers (BD Bios-
ciences, USA) pre-coated with BD Matrigel matrix were
used according to the manufacturer’s protocol. The assay
insert plates were prepared by rehydrating the BD Matri-
gel Matrix coating with phosphate buffered saline for
two hours at 37 °C. The rehydration solution was care-
fully removed, and 2.5x105 cancer cells were added to
each apical chamber and 0.75 ml of RPMI-1640 contain-
ing chemo attractant (10% FBS) was added to the basal
chamber. Uncoated insert plates, included as invasion
controls, were used without rehydration. Assay plates
were incubated for 22 hours at standard culturing condi-
tions. Then, 2.5 μg/ml calcein AM was added to 20 μl
DMSO, and 10 μl of this solution was transferred to
12 ml Hanks Buffered Saline Dispense. Next, 0.5 ml cal-
cein solution was transferred into each well of a 24-well
plate. The medium from the insert was removed, and
multiwell inserts were transferred to the plate containing
0.5 ml/well calcein. Plates were incubated for an hour at
standard culture conditions. The fluorescence of the
invaded cells was measured with an excitation wave-
length of 485 nm and an emission wavelength of 530 nm
using a Tecan Infinite 200 Reader (Tecan, USA).
To characterise the growth of the cancer cell lines, they
were treated with trypsin and resuspended in the culture
medium. Thirty-five-mm culture plates (Corning Inc.)
were coated with 100 μl of growth factor reduced Matrigel
(BD Biosciences, USA) and left to solidify for 30 min at
37 °C. The cells were then plated at a concentration of 104
cells/ml. The growth of cells on Matrigel was observed
each day under a phase-contrast microscope.
SDS-PAGE and western blot
The cells were pelleted by centrifugation at 400 x g at 4 °C
for 5 min. Protein extracts from cultured cells were iso-
lated by lysis of the collected pellets with RIPA buffer
(50 mM Tris, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1%
NP-40, 0.25% Na-deoxycholate and 1 mM PMSF) supple-
mented with a protease inhibitor cocktail (Sigma-Aldrich,
USA) and a phosphatase inhibitor cocktail (Sigma-
Aldrich, USA) for 30 min at 4 °C. Lysates were cleared for
20 min at 16,000 x g, and supernatants were collected.
The protein concentration in the lysates was determined
by Bio-Rad Protein Assay Dye (Bio-Rad Laboratories Inc.,
USA). Cellular proteins extracted from canine and human
mammary cancer cell lines were analysed by SDS-PAGE
and subjected to immunoblotting analysis. Samples were
mixed with 4x NuPage sample buffer (Invitrogen, CA)
containing 100 mM DDT and heated to 95 °C for 5 min.
Lysates were subjected to electrophoresis using 3-8%NuPage Tris-Acetate precasting gels in Tris-Acetate SDS
Running buffer and transferred to a PVDF membrane
according to the manufacturer’s protocol. Membranes
were blocked for 2 hours at room temperature in Phos-
phate Buffered Saline (PBS), pH 7.2, containing 0.05%
Tween 20 (PBST) and 3% skimmed milk. Membranes
were then washed with PBST and incubated at 4 °C over-
night with the anti DF3 (Imgenex, USA) and 115d8
(Abcam, UK) monoclonal antibodies, diluted 1:100 in 1%
milk/PBST and anti-ß-actin antibodies (Santa Cruz Bio-
technology, USA) diluted 1:1.000 in 1% milk/PBST (as a
reference protein). Detection was performed by the Super-
Signal West Pico Chemiluminescence Substrate using an
anti-mouse antibody conjugated with horseradish peroxid-
ase (Pierce Biotechnology, USA).
Animals, serum biochemistry, histology and
immunohistochemistry
Fifty tissue samples were obtained from female dogs
with malignant mammary tumours during surgery in
private clinics; 27 were solitary nodules, and 22 were
multiple nodules presenting simultaneously with 2 or
more lumps. In one case, data were not available.
To select only primary tumours without lymph node
involvement and lung metastasis, the female dogs were
initially submitted to a systematic clinical examination
together with a macroscopic evaluation of the tumour
and the lymph nodes to accomplish a staging categorisa-
tion. Several clinical factors, such as tumour size, the
presence/absence of tumour metastasis to regional
lymph nodes and the presence/absence of distant metas-
tases, were used as a staging system (TNM), according
to Philbert [21]. As part of the diagnostic workup, the
altered regional lymph nodes were evaluated by means
of a tough fine needle aspirate (FNA) and cytology.
Thoracic radiological examinations searching for lung
metastases were also performed. A routine clinicopatho-
logical examination (blood cell count, serum biochem-
ical profile and urinalysis) to exclude specific benign
conditions that could influence the serum levels of CA
15–3 (acute hepatitis, chronic liver diseases, chronic
renal failure, and dermatological conditions) was also
performed in all animals. To determine factors that pos-
sibly influence serum CA 15–3 activity in cancer
patients, the impact of clinical and pathological para-
meters were investigated and cases were assessed for
tumour size, skin ulceration, histological type, tumour
grade, inflammation and necrosis. Unfortunately, the
data for the length of survival time were unavailable for
most patients.
Peripheral venous blood samples were obtained from
the patients during the pre-operative stage to measure
CA 15–3. The anticoagulated whole blood from patients
subjected to a mastectomy was collected for routine
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samples was collected for our analyses (with the written
permission of the dogs’ owners). Sera were separated
and stored at −20 °C until use. CA 15–3 levels were
determined by a direct chemiluminescent technology in
the automated immunoanalyser system ADVIA Cen-
taurW using a kit for human diagnostic oncology (Bayer
Immuno 1 CA 15-3™ assay) according to the manufac-
turer's protocol. Values were expressed as Units/ml (U/ml).
As a control group, we used data obtained in our previous
study [15].
For histological examinations, representative portions
of tissue samples were fixed in 10% buffered formalin
and then dehydrated and embedded in paraffin. Three to
4-micron-thick consecutive sections were cut and stained
with haematoxylin and eosin (HE) and subjected to the
immunohistochemical procedure using the anti MUC1
antibodies previously described. To better investigate the
pattern of expression on canine mammary tissues, the
immunohistochemical procedure was also applied on 5
normal lesions and on 10 benign breast lesions (3 com-
plex adenomas, 2 simple adenomas, 2 benign mixed
tumours and 3 dysplastic lesions) obtained from the
archive of the Laboratory of Histopathology of the Isti-
tuto Zooprofilattico Sperimentale dell’Umbria e delle
Marche.
In HE sections, tumours were classified according to
the WHO’s criteria for canine mammary neoplasms [3]
and coded according to the WHO’s International Classi-
fication of Disease for Oncology System (ICD-O). In
cases of multiple nodules in a chain, the entire chain
was resected, and all nodules were subjected to hist-
ology. Only the tumour with the higher grade of malig-
nancy was used as the basis for a comparison with CA
15–3.
Histological grading was evaluated in accordance with
Elston and Ellis [22], the most current method for the
histological grading of human breast cancers, recently
applied to canine mammary tumours and more practical
for the comparison of data between researchers [23-25].
According to this method, histological findings were
recorded and used to classify mammary carcinomas as
grade I, grade II or grade III tumours.
For immunohistochemistry (IHC), tissue sections were
hydrated utilising xylene and a graded alcohol series.
Successively, the quenching of endogenous peroxidase
activity was achieved by incubating the sections for
30 min in 3% hydrogen peroxide in methanol at room
temperature. Antigen retrieval was performed using
microwave exposure for 5 min at 650 W (three times)
and 500 W (two times) in a citrate buffer solution (pH
6.0). Primary antibodies (diluted 1:50 in PBS) were ap-
plied and incubated overnight at 4 °C in a humidified
chamber. A streptavidin-biotin revelation commercial kit(Dako, DK) was used, and the reaction was developed by
3,3’-diaminobenzidine (DAB). The slides were washed in
tap water and counterstained with Mayer’s haematoxylin.
A positive control of human malignant breast cancer tis-
sue was included in each staining. Negative control
slides were incubated with a specific non immune anti-
body in parallel with each staining batch to confirm the
antibody specificity.
To evaluate MUC1 expression, a semi-quantitative
method was performed; protein expression was assessed
estimating the percentage of labelled cells and scored as
follows: no staining, weak staining (≤20%), moderate
(≥20 ≤50%) and strong (≥50%) immunostaining. The
images were digitalised using a video camera connected
to a microscope (DMR Fluo HC, Leica, USA), and the
semi-quantitative evaluation was estimated by counting
1.000 positive cells in randomly selected fields (magnifi-
cation 200x), avoiding necrosis.
Statistical analysis
The statistical analysis was conducted using Prism version
5.00 software (GraphPad Software, USA). The ANOVA
and post-hoc Dunett`s Multiple Comparison test and
Tukey’s Honestly Significance Difference (HSD) were ap-
plied. To assess the correlation between the tumour char-
acteristics and the CA 15–3 serum level, the Pearson
correlation coefficient was used. A p< 0.05 was regarded





Each tumour cell line used in this study showed cytoplas-
mic expression of MUC1, and the positivity was mainly
observed in a granular pattern. Frequently, cytoplasmic
staining was observed together with a membrane reaction
in a mixed pattern. CMT-W1, CMT-W1M, CMT-W2 and
CMT-W2M cell lines showed a high expression of MUC1,
whereas CMT-U27, CMT-U309 and P114 cell lines
showed weak 115d8 expression. The same results were
obtained using antibodies against DF3 (data not shown).
The mean optical density (Arbitrary Units) of brown
coloured antigen reflecting 115d8 expression was counted.
As a control, the MCF7 cell line was used, which
expresses the antigen at the level of 137.6 (±SE: 4.27). No
significant differences were found between the expression
of the DF3 antigen in the control cell line and in the fol-
lowing cell lines: CMT-W1 (124.7; ±SE:3.65), CMT-W1M
(128.8; ±SE: 3.25), CMT-W2 (129.9; ±SE: 4.39), and CMT-
W2M (140.2; ±SE: 1.47). A significant difference (p< 0.05)
was found between the 115d8 expression in the MCF7 cell
line and the CMT-U309 cell line (121.6; ±SE: 1.57),
whereas highly significant differences (p< 0.001) were
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cell lines (105.3; ±SE: 3.36 and 96.57; ±SE: 2.30, respect-
ively) in comparison with MCF7 (Figure 1).
Invasion of canine mammary cancer cell lines
The invasion assay results and growth characteristics on
the Matrigel matrix of the canine mammary cancer cell
lines CMT-U27, CMT-U309, P114, CMT-W1 and
CMT-W2 have previously been reported [20]; however,
these cell lines have not been compared with CMT-
W1M and CMT-W2M cell lines. The assay showed that
only CMT-W1, CMT-W1M, CMT-W2 and CMT-W2M
cells migrated through the Matrigel (Figure 2A). The
fluorescence intensity related to the migration of the
CMT-W1 cells was 17.57 (p< 0.05 compared with non-
migrating cells), and the migration of the CMT-W1M
cells was 17.00 (p< 0.05 compared with non-migrating
cells), whereas migration of the CMT-W2 and CMT-
W2M cells was 38.00 (p< 0.001 compared with non-
migrating cells) and 17.00 (p< 0.05 comparing with
non-migrating cells), respectively.
To confirm the ability of these cell lines to invade the
matrix, we have assessed their growth characteristics on
the Matrigel matrix (Figure 2B). After 22 hours of cul-
turing (similarly as in the invasion assay) on Matrigel,
the CMT-U27, CMT-U309 and P114 cell lines formed
colonies, whereas the CMT-W1, CMT-W1M, CMT-W2
and CMT-W2M cell lines formed branching structures
(Figure 2B), which indicated their invasive phenotype.
SDS-PAGE and western blot
Immunoblot analysis using anti 115d8 antibodies revealed
the presence of two reactive protein bands in the humanFigure 1 MUC1/CA 15–3 expression in canine mammary cancer cell li
mammary carcinoma cells and canine mammary cancer cell lines: P114, CM
obtained with an Olympus BX60 microscope (at the magnification of 200x)
mean MUC1 expression (and SE) in the examined cell lines. Ten pictures in
a computer-assisted image analyser (Olympus Microimage™ Image Analysis
performed using Prism version 5.00 software (GraphPad Software, USA). Th
applied to analyse the MUC1 expression in the examined cell lines (the MC
highly significant and marked as ***, whereas p< 0.05 was regarded as sigMCF7 cell line, used as a positive control (indicated by
arrows in Figure 3 lane 1). The band with a lower molecu-
lar weight (MW) is approximately 250 kDa, while the
MW of the major protein band appears to be more than
300 kDa. A single protein band, with the same high MW
as the positive control, was detected for the CMT-W1 and
CMT-W2 cell lines (Figure 3, lanes 3 and 4), as well as for
the CMT-W1M and CMT-W2M cell lines (Figure 3, lanes
7 and 8). No bands were observed for the CMT-U309,
CMT-U27 and P114 cell lines (Figure 3, lanes 2, 5 and 6).
Immunoblotting performed with the anti DF3 antibody
gave overlapping results (data not shown).
The Western blot analysis with anti ß-actin antibodies
showed that variability in protein loading could not ac-
count for the observed differences in 115d8 expression.
Animals, serum biochemistry, histology and
immunohistochemistry
Most dogs in our series were mixed breeds (32.3%), fol-
lowed by German Shepherd dogs (11.8%). The mean age
was 9.2 ±2.4 years (range 3–17), with an increased
prevalence among intact females (79.4%). The mean
diameter of nodules was 3.09 ± 2.90 cm (range 0.5-
12 cm), and skin ulceration was present in 22% of cases.
None of these patients had apparent nodal involvement.
With respect to the histopathological analyses based
on the WHO’s classification, complex carcinoma was the
most common type of tumour (68%) followed by simple
carcinoma (28%) and carcinosarcoma (4%); necrosis and
inflammation were observed in 62% and 42% of cancer
cases, respectively. According to Elston and Ellis’s method,
66% of tumours were classified as grade I, 28% were classi-
fied as grade II and 6% were classified as grade III.nes and the human MCF7 cell line. A. Pictures of MCF7 human
T-U27, CMT-U309, CMT-W1, CMT-W1M, CMT-W2 and CMT-W2M
. The MUC1 antigen is reflected as a brown colour. B. The graph of the
each slide were analysed. The brown colour intensity was counted by
, software version 4.0 for Windows, USA). The statistical analysis was
e ANOVA and Dunett`s Multiple Comparison post-hoc test were
F7 cell line was regarded as a control); p< 0.001 was regarded as
nificant and marked as *.
Figure 2 Invasion of canine mammary cancer cell lines. A. The graph of fluorescence intensity related to the invasion of canine mammary
cancer cell lines: CMT-U27, CMT-U309, P114, CMT-W1, CMT-W1M, CMT-W2 and CMT-W2M. The statistical analysis was performed using Prism
version 5.00 software (GraphPad Software, USA). The ANOVA+ Tukey’s test were applied to analyse the results. p< 0.05 was regarded as
significant and marked as *, whereas p< 0.001 was regarded as highly significant and marked as ***. B. Growth characteristics of the CMT-U27,
CMT-U309, P114, CMT-W1, CMT-W1M, CMT-W2 and CMT-W2 cell lines (phase contrast micrographs) grown on Matrigel matrix for 24 hours.
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thermore, dogs with malignant mammary tumours had a
significantly higher median activity of serum CA 15–3Figure 3 Western blot analysis of the cellular extracts from
human and canine mammary cell lines. Representative Western
blot picture of MUC1 expression in the examined cancer cell lines:
Lane 1: human breast cancer cell line MCF-7; Lane 2: canine
spindle-cell tumour cell line CMT-U309; Lanes 3 and 4: canine
mammary adenocarcinoma cell lines CMT-W1 and CMT-W2; Lane 5:
canine mammary carcinoma cell line CMT-U27; Lane 6: canine
mammary anaplastic cancer cell line P114; Lanes 7 and 8: canine
mammary metastatic cancer cell lines CTM-W1 and CTM-W2.(0.80 ± 0.55) than the control group (0.57 ± 0.21)
(p= 0.004). When we compared tumour Carbohydrate
antigen 15–3 serum levels and the pathological variables
considered in this study, no statistically significant differ-
ences between CA 15–3 and age, history of ovariohyster-
ectomy, numbers and sizes of tumour and histological
types were observed (Table 1). Furthermore, because the
inflammatory and necrotic processes were often associated
with cancer, they did not appear to have influenced the
serum levels of CA 15–3. Interestingly, a highly significant
correlation was found between CA 15–3 serum levels and
the tumour grade (p <0.0019). In grade I tumours, the
average concentration of this marker was approximately
half (0.64 U/ml) compared with that of grades II (1,21
U/ml) and III (1,33 U/ml). Given the fact that grade III
neoplasms were represented by a small number (n. 3
cases) and that their corresponding mean serum level was
not significantly different from grade II tumours, they
were included in the same group.
With immunohistochemistry, DF3 antigen was detected
in all normal gland tissues, and, as expected, the immu-
noreactivity was almost restricted to the apical membrane
of epithelial cells, which displayed a weak to moderate
Table 1 The relation of CA 15–3 serum concentration to





Tumour size (cm) <2 0.70 ± 0.67 n.s.
2-5 0.84 ± 0.45 n.s.
>5 1.03 ± 0.54 n.s.
Skin ulceration Yes 0.54 ± 0.15 n.s.
No 0.91 ± 0.63 n.s.
Histopathology Simple carcinoma 0.63 ± 0.40 n.s.
Complex carcinoma 0.78 ± 0.57 n.s.
Carcinosarcoma 1.50 ± 0.28 n.s.
Inflammation Yes 0.64 ± 0.46 n.s.
No 0.90 ± 0.60 n.s.
Necrosis Yes 0.80 ± 0.59 n.s.
No 0.80 ± 0.53 n.s.
Histological grade Grade I 0.64 ± 0.36 n.s.
Grade II 1.21 ± 0.79 0.0019
Grade III 1.33 ± 0.32 0.0019
Relation between tumour size, skin ulceration, histopathological diagnosis,
inflammation, necrosis and histological grade of canine mammary cancer
tissues and serum CA 15–3 levels. The Pearson correlation coefficient was
applied using Prism version 5.00 software (GraphPad Software, USA).
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lial cells and in luminal secretions (Figure 4A).
In benign mammary lesions (hyperplastic and neo-
plastic), the staining was observed in 7/10 (70%) of the
analysed cases, and the pattern of reaction was weak-to-
moderate, usually restricted to the apical membrane of
the epithelial cells. Approximately 20% of normal ducts
also showed a slight apical staining. In complex aden-
omas, simple adenoma and benign mixed tumours, a
cytoplasmic stain was also detected (Figure 4B), while in
the dysplastic lesions (n.1 adenosis and n. 2 fibrocystic
disease), no evidence of reaction was found.
In malignant mammary tumours, the apical staining
was almost always observed together with a cytoplasmic
expression in a mixed pattern with variable intensity
and mostly in diffuse or granular pattern. It is import-
ant to note that the reaction affected all of the cells in
34 (68%) carcinoma samples, including 20 (59%) with
strong and 14 (41%) with moderate staining. In com-
plex carcinomas, epithelial cells showed a diffuse posi-
tivity in 24 (70.6%) cases, with a greater intensity at the
periphery of the neoplastic foci (Figure 4C). In the mar-
ginal areas of invasive tumours, markedly positive neo-
plastic cells invading the surrounding adipose tissue
were frequently observed (Figure 4D). In simple carcin-
omas, a diffuse expression was detected in 12 (85.7%)
cases and most evident in the apical membrane ofneoplastic cells that formed tubular structures (Fig-
ure 4E). This tumour had a strong tendency to infil-
trate the surrounding vessels, and lymphatic emboli,
when present, exhibited a strong cytoplasmic positivity
(Figure 4F). In carcinosarcomas, DF3 expression was
very weak in 100% of cases because the sarcomatous
cells were preponderant and only a few stained epithe-
lial cells were observed. In hyperplastic or normal
lobules that sometimes circumscribed the tumour pro-
liferated areas, a weak positivity was also detected. In
all of the tissues examined, myoepithelial and stromal
cells, lymphocytes, macrophages and blood vessels did
not express immunoreactivity. No significant correla-
tions were found between DF3 overexpression and
serum CA 15–3 levels.
Discussion
In veterinary medicine, a variety of assays and techni-
ques have been used in an attempt to identify the prog-
nostic markers for neoplastic diseases, including clinical
parameters, histologic features, immunohistochemistry,
quantitative PCR, evaluation for genomic mutations
and specific serum protein levels or enzyme activity
analyses [26].
To investigate the potential functional relevance of CA
15–3 as a serum tumour marker in veterinary oncology,
we performed a multidisciplinary study on canine neo-
plastic mammary tissues and cell lines.
The main finding in Western blot analysis regarded
the positive interaction between the human antibodies
and the canine MUC1 protein. The protein sequence of
epitope DF3 in humans is TRPAPGS [27], whereas the
canine DF3 epitope sequence is SRPAPSS (protein
sequences have been obtained from NCBI with acces-
sion numbers [canine NP_001181906.1 and human
P15941.3] and then compared using the MultAlin on-
line platform [28]). We used the BLOSUM62 amino
acid substitution matrix [29,30] to score alignments be-
tween evolutionarily divergent protein sequences. It
revealed a high similarity between these two epitopes in
humans and in dogs (with only one point of difference).
Thus, theoretically, the similarity of the protein se-
quence of the DF3 epitope is very high in these two
species. Nevertheless, the results of WB showed that
anti 115d8 and anti DF3 antibodies display cross-
reactivity with canine samples. The ICC analysis of the
MUC1 expression (using both antibodies) in canine
mammary cancer cell lines showed staining patterns
similar to those observed in humans.
In WB, a double protein band with a high molecular
weight was observed in MCF-7 cells [31-33]. In the ca-
nine tumour cell lines CMT-W1, CMT-W2, CMT-W1M
and CMT-W2M, we found a single protein band of
MUC1 with a molecular weight similar to the higher
Figure 4 MUC1 expression in the canine normal mammary gland and in benign and malignant mammary lesions. Sections of specimens
stained immunohistochemically. MUC1 immunoreactivity was present in normal tissues samples, showing luminal and apical expression (A).
Moderate and heterogeneous labelling of epithelial cells in complex adenoma (B). Higher level of immunoreactivity in complex carcinoma (C), in
cancer cells invading the adipose tissue (D), in simple carcinoma (E) and in intra lymphatic metastatic cells (F). The images were digitalised using
a video camera connected to a microscope (DMR Fluo HC, Leica, USA), and the semi-quantitative evaluation was estimated by counting 1.000
positive cells in randomly selected fields (magnification 200x) avoiding necrosis.
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the chemical exposure, some films revealed an apparent
reactive point with a molecular weight of approximately
250 kDa. These data are still under investigation because
it is difficult to determine whether it is an actual protein
band or an artefact of the analysis, considering the low
sensitivity of the test.
Our immunocytochemistry results differ from those
obtained using Western blot. The immunocytochemical
examination revealed MUC1 expression in all of the
examined cell lines. However, only the CMT-W1, CMT-
W1M, CMT-W2 and CMT-W2M cell lines expressed
MUC1 at high levels, similar to MCF7 (no statistically
significant differences were found). The remaining cell
lines exhibited a weaker expression of MUC1, which dif-
fered significantly from the MCF7 cell line. According to
the subject data [34,35], a higher expression of MUC1 is
observed in more invasive metastatic cancer. Our find-
ings support this hypothesis, as CMT-W1, CMT-W1M,
CMT-W2 and CMT-W2M cell lines with invasive phe-
notypes [17,18,20] (Figure 2) showed a higher MUC1expression (detected in WB and ICC). Thus, a lack of
MUC1 expression in non-invasive P114, CMT-U27 and
CMT-U309 cell lines in Western blot analysis may be
due to low levels of this antigen expression and/or the
low sensitivity of the Western blot analysis. Although
both methods detect a specific protein expression, they
significantly differ from each other on what may explain
the differences in the obtained results. Similar variations
between the results obtained using Western blot and im-
munocytochemistry have previously been reported [36],
showing that immunocytochemistry is a more sensitive
method than the Western blot in cases of weak antigen
expression.
Statistical analysis allowed us to demonstrate that CA
15–3 serum levels correlate positively with the degree of
tumour proliferation and differentiation, as a significantly
higher concentration of CA 15–3 was found in grades II-
III than in grade I carcinomas (p= 0.0019). Tumour size,
skin ulceration, necrosis, inflammation and the histo-
logical type of mammary cancer were not significantly
related to the serum levels of CA 15–3.
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levels and tumour grading appears to be logical because
we assumed that tumour markers reflect the number and
the activity of neoplastic cells as well as their products that
access the circulation where the marker is measured.
Therefore, this parameter could be taken into consid-
eration as potentially enabling a better evaluation of a
tumour’s malignancy, particularly for establishing the
preoperative stage of the neoplasm and providing useful
guidelines when determining the surgical approach.
Another finding of our study, as expected, is the ex-
pression of MUC1 in normal canine mammary tissues
and in mammary gland benign lesions. The reaction was
primarily restricted to the apical membrane of epithelial
cells. However, in benign tumours, the pattern of reac-
tion was extended to the cytoplasm of the luminal epi-
thelial cells. These results are in absolute parallel to
those observed in human mammary tissues. [37].
Among the carcinomas, we observed MUC1 activity in
68% of the analysed cases that displayed a strong immu-
nostaining in a mixed pattern (involving the entire cell
surface and the cytoplasm), which comprises the whole
cell population in several carcinoma samples. This find-
ing is in accordance with the observation of Lacunza
[38], which demonstrated a correlation between MUC1
protein over-expression and gene amplifications in be-
nign and malignant breast tumours. Many studies have
revealed that this event could be linked to the presence
of membrane-associated MUC1 molecular portions that
are shed from the surface of tumour cells to the cytosol
by modulation of its glycosylation state [39,40].
In the present study, there was no significant correl-
ation between the over-expression of MUC1 and CA
15–3, the circulating form of the DF3 antigen. However,
a significant correlation has been found between the
histopathological grade of the tumour malignancy and
MUC1 expression and between the histopathological
grade of the tumour malignancy and the circulating CA
15–3 level. We suppose that a lack of a correlation be-
tween MUC1 over-expression in tissues and the serum
level of CA 15–3 may be related to the different anti-
bodies used in the IHC and CA 15–3 tests.Conclusions
To the best of our knowledge, this is the first report dem-
onstrating a significant correlation between serum CA
15–3 expression and tumour malignancy in dogs with
mammary cancer. Our results may provide the basis for
developing a novel approach in veterinary research, al-
though additional studies using a large number of healthy
and pathological clinical samples to validate these prelim-
inary results and to establish normal and pathological
serum ranges of CA 15–3 antigen in dogs.Clearly, this pilot study is only the beginning of under-
standing the potential application of this serum tumour
marker in canine mammary cancer management, and we
hope that these findings will encourage future research
work in this field.
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